Recruiting
Phase 1

Tibetree PRPs

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07447856

Conditions

Cancer Patients

Survivor Patients

Cancer Pain

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Topical herbal plaster

Study Details

Brief summary:

The are doing this study to find out whether using topical (on the skin) herbal plasters, Tibetree pain- relieving plasters (PRPs), can be an effective addition to standard opioid therapy for pain management. The researchers will look at whether the Tibetree PRPs are a practical (feasible) and effective way of managing localized pain (pain that is limited to a certain area) in people who are currently taking opioids. Participants in this study will have cancer or have had it in the past.

Conditions

Cancer Patients

Survivor Patients

Cancer Pain

Study ID

NCT07447856

Start date

Feb 23, 2026

Status verified date

Feb, 2026

Completion date

Feb, 2028

Anticipated

Primary completion date

Feb, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • English speaking with age ≥ 18 years or older
  • A diagnosis of cancer with no restrictions placed on type of cancer or stage. Eligibility criteria will not be restricted to MSK confirmed biopsy/diagnosis. Outside institution's testing is sufficient.
  • Ambulatory (Karnofsky Performance Status of ≥ 60)
  • Having one of three types of pain (e.g., musculoskeletal pain, bone metastasis pain, and visceral/abdominal pain) and the worst pain area can be covered by one patch of topical herbal plaster
  • Worst pain score (measured by the 0-10 numeric pain rating scale) 4 or above in the preceding week
  • Current use of short-term oral opioids (i.e. oxycodone, morphine immediate release, or hydromorphone) for pain management.
  • Willingness to adhere to and understanding of all study-related procedures, including randomization to one of the two possible study arms
  • Able to understand informed consent and provide signed informed consent form

Exclusion Criteria:

  • Patients are unwilling to reduce opioid use if their pain reduces
  • Patients have generalized musculoskeletal pain such as fibromyalgia as primary source of pain
  • Patients with clinician confirmed significant skin disorders such as severe eczema, psoriasis, severe xerosis, chronic dermatitis, or adhesive allergy.
  • Patients with open wounds, infections, skin trauma at skin overlying area of pain
  • Patients with documented history of skin sensitivity to adhesive or allergic reaction to other patches or topical analgesics
  • Patients with documented skin allergic reaction to plants or herbs
  • Patients who are unwilling to hold their current localized topical pain treatment (such as lidocaine patch) for the most severe pain site.
  • Patients who undergo initiation or change in pain management strategies within 1 week prior to enrollment, including oral analgesics (e.g., opioids, NSAIDs), medications that can significantly reduce pain (e.g., bisphosphonates, denosumab), or interventional procedures (e.g., nerve blocks, palliative radiation).
  • Patients who are planned to undergo initiation or change of the above pain management strategies in the 2 weeks following enrollment.
  • Patients who undergo initiation or change in standard cancer treatments (surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, or targeted therapy) 1 week prior to enrollment.
  • Patients who are planned to undergo initiation or change of active cancer treatments (surgery, radiation, chemotherapy, hormonal therapy, immunotherapy, or targeted therapy) in the 2 weeks following enrollment.

Study Design

Enrollment

150 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Topical herbal plaster

Will use the Tibetree PRPs on Days 1-7 of the treatment period.

active comparator: Waitlist control group (WLC)

Will use the Tibetree PRPs on Days 8-14 of the treatment period after a 7-day waiting period

Interventions

Topical herbal plaster

Participants will receive topical herbal plaster once a day for up to 8 hours daily for 7 days.

Primary outcome measure

  • Enrollment rate [ Time Frame: 2 years ]
  • Treatment adherence rate [ Time Frame: 2 years ]
  • Assessment completion rates [ Time Frame: 2 years ]
  • Treatment satisfaction [ Time Frame: day 7 ]

Central Contacts and Locations

Central contacts

Jun Mao, MD, MSCE

646-888-0863maoj@mskcc.org

Kevin Liou, MD

646-608-8563

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Bergen (All Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Westchester (All Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Jun Mao, MD, MSCE

646-888-0863

Memorial Sloan Kettering Nassau (All Protocol Activities)

Recruiting

Rockville Centre, New York, United States, 11553

Contacts

Jun Mao, MD, MSCE

646-888-0863

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Mar 4, 2026

Last verified

Feb, 2026

Keywords

  • Tibetree
  • Tibetree Pain-Relieving
  • Cancer
  • Pain
  • Cancer survivor
  • 25-376

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-03-04.